Liposomal Irinotecan clinical trials
Liposomal Irinotecan is named as an intervention in 18 current clinical trials in our China, USA, France, Spain, Japan, Germany, South Korea, Taiwan, UK, Poland, Brazil, Israel, Italy, Netherlands and Mexico registers. 7 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Hebei Medical University Fourth Hospital (3). The most-studied condition is Pancreatic Cancer.
Patient leaflets for Liposomal Irinotecan
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Liposomal Irinotecan
18 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Liposomal Irinotecan
23 conditionsAll 23 conditions
| Condition (as registered) | Trials |
|---|---|
| Pancreatic Cancer | 2 |
| Metastatic Pancreatic Cancer | 2 |
| Metastatic Pancreatic Adenocarcinoma | 2 |
| Rectal Cancer | 2 |
| Solid Tumor | 1 |
| PDAC | 1 |
| PDAC - Pancreatic Ductal Adenocarcinoma | 1 |
| Osteosarcoma | 1 |
| Osteosarcoma Metastatic | 1 |
| Rectal Cancer, Adenocarcinoma | 1 |
| Malignant Ascites | 1 |
| Advanced Solid Malignancies | 1 |
| Biliary Tract Cancer (BTC) | 1 |
| ESCC | 1 |
| Pancreas Ductal Adenocarcinoma | 1 |
| Rectal Cancer Patients | 1 |
| Colorectal Cancer | 1 |
| Pancreatic Ductal Adenocarcinoma (PDAC) | 1 |
| Metastatic Colorectal Cancer (CRC) | 1 |
| Liposomal Irinotecan | 1 |
| Second-Line | 1 |
| Esophageal Cancer | 1 |
| Stage IV Pancreatic Cancer AJCC v8 | 1 |
Sponsors
lead sponsor per trial+ 1 more sponsors in the trial list above.
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Liposomal Irinotecan trials
How many clinical trials are testing Liposomal Irinotecan?
18 current trials in our China, USA, France, Spain, Japan, Germany, South Korea, Taiwan, UK, Poland, Brazil, Israel, Italy, Netherlands and Mexico registers name Liposomal Irinotecan as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Liposomal Irinotecan trials recruiting patients?
Yes. 7 of the 18 trials are recruiting: 7 with sites in China, 2 with sites in USA, 2 with sites in France, 2 with sites in Spain, 2 with sites in Japan, 1 with sites in Germany, 2 with sites in South Korea, 1 with sites in Taiwan, 1 with sites in UK, 1 with sites in Poland, 1 with sites in Brazil and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Liposomal Irinotecan clinical trials?
Hebei Medical University Fourth Hospital (3), Astellas Pharma Global Development, Inc (1), Astellas Pharma Inc (1) and Revolution Medicines, Inc (1), among 16 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Liposomal Irinotecan works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Liposomal Irinotecan works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Liposomal Irinotecan (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.